Brokerages expect Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to post earnings per share of $2.36 for the current quarter, according to Zacks. Eight analysts have provided estimates for Alexion Pharmaceuticals’ earnings. The highest EPS estimate is $2.51 and the lowest is $2.30. Alexion Pharmaceuticals reported earnings per share of $2.07 during the same quarter last year, which suggests a positive year over year growth rate of 14%. The firm is expected to announce its next quarterly earnings results on Thursday, July 25th.
According to Zacks, analysts expect that Alexion Pharmaceuticals will report full year earnings of $9.49 per share for the current fiscal year, with EPS estimates ranging from $9.31 to $9.97. For the next year, analysts expect that the firm will report earnings of $10.48 per share, with EPS estimates ranging from $8.93 to $12.22. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Alexion Pharmaceuticals.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported $2.39 EPS for the quarter, beating the consensus estimate of $1.99 by $0.40. Alexion Pharmaceuticals had a net margin of 9.59% and a return on equity of 19.53%. The company had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.13 billion. During the same quarter in the previous year, the company earned $1.68 earnings per share. Alexion Pharmaceuticals’s revenue for the quarter was up 22.5% on a year-over-year basis.
ALXN has been the subject of a number of research reports. BidaskClub cut shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, February 7th. Guggenheim reissued a “neutral” rating and issued a $135.00 price target on shares of Alexion Pharmaceuticals in a research note on Thursday, March 21st. Credit Suisse Group reissued a “buy” rating and issued a $156.00 price target on shares of Alexion Pharmaceuticals in a research note on Tuesday, January 22nd. Zacks Investment Research cut shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, February 12th. Finally, Cowen restated a “buy” rating and issued a $165.00 price objective on shares of Alexion Pharmaceuticals in a report on Wednesday, March 13th. Six equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $162.25.
Several hedge funds have recently modified their holdings of the company. FMR LLC lifted its holdings in shares of Alexion Pharmaceuticals by 25.1% in the fourth quarter. FMR LLC now owns 26,398,265 shares of the biopharmaceutical company’s stock valued at $2,570,135,000 after purchasing an additional 5,301,272 shares in the last quarter. Vanguard Group Inc lifted its stake in Alexion Pharmaceuticals by 1.2% during the third quarter. Vanguard Group Inc now owns 15,811,291 shares of the biopharmaceutical company’s stock worth $2,197,928,000 after purchasing an additional 192,857 shares during the period. Jennison Associates LLC lifted its stake in Alexion Pharmaceuticals by 17.3% during the first quarter. Jennison Associates LLC now owns 10,241,457 shares of the biopharmaceutical company’s stock worth $1,384,440,000 after purchasing an additional 1,512,545 shares during the period. Artisan Partners Limited Partnership lifted its stake in Alexion Pharmaceuticals by 220.9% during the first quarter. Artisan Partners Limited Partnership now owns 4,248,248 shares of the biopharmaceutical company’s stock worth $574,278,000 after purchasing an additional 2,924,550 shares during the period. Finally, Norges Bank bought a new position in Alexion Pharmaceuticals during the fourth quarter worth about $388,934,000. Institutional investors and hedge funds own 94.82% of the company’s stock.
ALXN stock traded up $3.50 during midday trading on Friday, reaching $131.91. The company had a trading volume of 65,642 shares, compared to its average volume of 1,511,350. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.87 and a quick ratio of 3.36. Alexion Pharmaceuticals has a 1 year low of $92.56 and a 1 year high of $141.86. The stock has a market cap of $29.37 billion, a PE ratio of 18.58, a P/E/G ratio of 0.99 and a beta of 1.53.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Further Reading: Strike Price
Get a free copy of the Zacks research report on Alexion Pharmaceuticals (ALXN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.